Mark Pegram

Medical oncologist, Breast specialist

Susy Yuan-Huey Hung Professor
Mark D. Pegram, MD, is the first director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center. He is also the co-director of Stanford’s Molecular Therapeutics Program. He is a renowned clinician and scholar in breast cancer research and a leader in translational medicine. Dr. Pegram played a major role in developing the drug Herceptin as a treatment for HER2-positive breast cancer, which constitutes about 20 percent of all cases. His laboratory experiments demonstrated that combining Herceptin with chemotherapy effectively killed cancer cells that overproduced the growth factor HER2. Dr. Pegram and others then conducted clinical trials showing that Herceptin improved survival rates and even cured some breast cancer patients. This remains one of the premier examples of bench-to-bedside translational research. Dr. Pegram’s current research efforts include a continued focus on the cancer-associated gene that encodes HER2 and developing new ways to target cancer cells expressing this protein. He is also pursuing strategies to target estrogen receptors, implicated in some 70 percent of all breast cancer cases.
Dr. Pegram earned his undergraduate and medical degrees from the University of North Carolina before joining the faculty of the University of California, Los Angeles. He spent five years at the University of Miami Miller School of Medicine, where he was a Sylvester Chair professor of medicine in the Braman Family Breast Cancer Institute and associate director for clinical research in the University’s Sylvester Comprehensive Cancer Center. He joined the Stanford faculty in 2012.

Breast Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Women's Cancer Center

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Board Certification: Medical Oncology, American Board of Internal Medicine (1993)

Board Certification: Internal Medicine, American Board of Internal Medicine (1989)

Internship: Univ Of Texas Southwestern (1987) TX

Residency: Univ Of Texas Southwestern (1987) TX

Fellowship: UCLA - School of Medicine (1993) CA

Medical Education: University of North Carolina (1986) NC

Honors & Awards

The Celebrity Cruises Award, The Breast Cancer Research Foundation (2013-2014)

2012 Keynote Lecture, American Radium Society 94th Annual Meeting, American Radium Society (29 April 2012)

Chair, Department of Defense Breast Cancer Research Program Integration Panel, Congressionally Directed Medical Research Programs, U.S. Army Research and Materiel Command (2012)

John G. Kuhn Lecture, Hematology/Oncology Pharmacy Association (21 March 2013)

6th Annual Connie Moskow Memorial Lectureship, Robert H. Lurie Comprehensive Cancer Center of Northwestern University (11 May 2012)

Sylvester Outstanding Cancer Research Award, University of Miami Sylvester Comprehensive Cancer Center (13 May 2011)

Administrative Appointments

Co-Director, Translational Oncology Research Program @ Stanford (TOP@S), Stanford Cancer Institute (2013 - Present)

Director, Stanford Breast Oncology Program, Stanford Cancer Institute (2012 - Present)

Associate Director for Clinical Research, Stanford Cancer Institute (2013 - Present)

Treating the HER2 Pathway in Early and Advanced Breast Cancer
Pegram, M. D. (2013). Treating the HER2 Pathway in Early and Advanced Breast Cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 27(4), 751-?.

Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.
Ward, T. M., IORNS, E., Liu, X., Hoe, N., Kim, P., & Pegram, M. D. (2013). Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene, 32(19), 2463-2474.

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.
Hurley, J., Reis, I. M., Rodgers, S. E., Gomez-Fernandez, C., Wright, J., & Pegram, M. D. (2013). The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast cancer research and treatment, 138(3), 783-794.

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells
Jegg, A.-M., Ward, T. M., Iorns, E., Hoe, N., Zhou, J., & Pegram, M. D. (2012). PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 683-692.

Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference
Toi, M., Benson, J. R., Winer, E. P., Forbes, J. F., von Minckwitz, G., & Inamoto, T. (2012). Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 919-926.

Comprehensive molecular portraits of human breast tumours
Koboldt, D. C., Fulton, R. S., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., & Palchik, J. D. (2012). Comprehensive molecular portraits of human breast tumours. NATURE, 490(7418), 61-70.

Tumor Biology Trumps Anatomy in Breast Cancer Brain Metastases
Pegram, M. D. (2012). Tumor Biology Trumps Anatomy in Breast Cancer Brain Metastases. ONCOLOGY-NEW YORK, 26(7), 666-?.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., & Glueck, S. (2012). Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 132(1), 215-223.

HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis
Houssami, N., Macaskill, P., Balleine, R. L., Bilous, M., & Pegram, M. D. (2011). HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. BREAST CANCER RESEARCH AND TREATMENT, 129(3), 659-674.

Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer
Smith, T. R., Liu-Mares, W., Van Emburgh, B. O., Levine, E. A., Allen, G. O., & Hu, J. J. (2011). Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. CARCINOGENESIS, 32(9), 1354-1360.

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., & Slamon, D. J. (2011). Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. JOURNAL OF CLINICAL ONCOLOGY, 29(2), 149-156.

Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene.
Harbeck, N., Pegram, M. D., Rüschoff, J., & Möbus, V. (2010). Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene. Breast care (Basel, Switzerland), 5(s1), 3-7.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., & Burstein, H. J. (2009). Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. ANNALS OF ONCOLOGY, 20(6), 1026-1031.

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
Pegram, M. D., Borges, V. F., Ibrahim, N., Fuloria, J., Shapiro, C., & Luck, N. C. (2009). Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. BREAST CANCER RESEARCH, 11(5).

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer
Storniolo, A. M., Pegram, M. D., Overmoyer, B., Silverman, P., Peacock, N. W., & Burris, H. A. (2008). Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 26(20), 3317-3323.

Biodistribution and predictive value of (IF)-I-18-fluorocyclophosphamide in mice bearing human breast cancer xenografts
Kesner, A. L., Hsueh, W.-A., Htet, N. L., Pio, B. S., Czernin, J., & Silverman, D. Hs. (2007). Biodistribution and predictive value of (IF)-I-18-fluorocyclophosphamide in mice bearing human breast cancer xenografts. JOURNAL OF NUCLEAR MEDICINE, 48(12), 2021-2027.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., & Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(1), 118-145.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., & Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 131(1), 18-43.

Predicting chemotherapy response to paclitaxel with F-18-fluoropaclitaxel and PET
Hsueh, W.-A., Kesner, A. L., Gangloff, A., Pegram, M. D., Beryt, M., & Silverman, D. Hs. (2006). Predicting chemotherapy response to paclitaxel with F-18-fluoropaclitaxel and PET. JOURNAL OF NUCLEAR MEDICINE, 47(12), 1995-1999.

Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status
Gordon, M. S., Matei, D., Aghajanian, C., Matulonis, U. A., Brewer, M., & Karlan, B. Y. (2006). Clinical activity of Pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. JOURNAL OF CLINICAL ONCOLOGY, 24(26), 4324-4332.

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., & Slamon, D. J. (2006). Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 24(12), 1831-1838.

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
Ryan, B. M., Konecny, G. E., Kahlert, S., Wang, H. J., Untch, M., & Duffy, M. J. (2006). Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. ANNALS OF ONCOLOGY, 17(4), 597-604.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G. R., & Slamon, D. J. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. CANCER RESEARCH, 66(3), 1630-1639.

Usefulness of 3 '-[F-18]fluoro-3 '-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy
Pio, B. S., Park, C. K., Pietras, R., Hsueh, W. A., Satyamurthy, N., & Silverman, D. Hs. (2006). Usefulness of 3 '-[F-18]fluoro-3 '-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. MOLECULAR IMAGING AND BIOLOGY, 8(1), 36-42.

Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with F-18-fluoropaclitaxel
Gangloff, A., Hsueh, W. A., Kesner, A. L., Kiesewetter, D. O., Pio, B. S., & Silverman, D. Hs. (2005). Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with F-18-fluoropaclitaxel. JOURNAL OF NUCLEAR MEDICINE, 46(11), 1866-1871.

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Yeon, C. H., & Pegram, M. D. (2005). Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 391-409.

Targeted therapy: Wave of the future
Pegram, M. D., Pietras, R., Bajamonde, A., Klein, P., & Fyfe, G. (2005). Targeted therapy: Wave of the future. JOURNAL OF CLINICAL ONCOLOGY, 23(8), 1776-1781.

Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny, G. E., & Pegram, M. D. (2004). Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology (Williston Park, N.Y.), 18(14), 32-36.

HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
Konecny, G. E., Thomssen, C., Luck, H. J., Untch, M., Wang, H. J., & Slamon, D. J. (2004). HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 96(15), 1141-1151.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., & Slamon, D. J. (2004). Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 96(10), 759-769.

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004). Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 96(10), 739-749.

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H. J., Bauerfeind, I., & Pegram, M. D. (2004). Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. CLINICAL CANCER RESEARCH, 10(5), 1706-1716.

Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.
Gilbert, C. W., McGowan, E. B., Seery, G. B., Black, K. S., & Pegram, M. D. (2003). Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker. Journal of experimental therapeutics & oncology, 3(1), 27-35.

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor
Pegram, M. D., & Reese, D. M. (2002). Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. SEMINARS IN ONCOLOGY, 29(3), 29-37.

Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
Pegram, M. D., & O'Callaghan, C. (2001). Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. Clinical breast cancer, 2, S15-9.

Docetaxel and Herceptin: Foundation for future strategies
Pegram, M. D. (2001). Docetaxel and Herceptin: Foundation for future strategies. ONCOLOGIST, 6, 22-25.

Trastuzumab and chemotherapeutics: Drug interactions and synergies
Pegram, M. D., Lopez, A., Konecny, G., & Slamon, D. J. (2000). Trastuzumab and chemotherapeutics: Drug interactions and synergies. SEMINARS IN ONCOLOGY, 27(6), 21-25.

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
Pegram, M. D., Konecny, G., & Slamon, D. J. (2000). The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer treatment and research, 103, 57-75.

A model-based approach for assessing in vivo combination therapy interactions
Lopez, A. M., Pegram, M. D., Slamon, D. J., & Landaw, E. M. (1999). A model-based approach for assessing in vivo combination therapy interactions. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 96(23), 13023-13028.

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
Aguilar, Z., Akita, R. W., Finn, R. S., Ramos, B. L., Pegram, M. D., & Slamon, D. J. (1999). Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. ONCOGENE, 18(44), 6050-6062.

Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
Pegram, M. D., & Slamon, D. J. (1999). Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. SEMINARS IN ONCOLOGY, 26(4), 89-95.

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
Pegram, M., HSU, S., Lewis, G., Pietras, R., Beryt, M., & Slamon, D. (1999). Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. ONCOGENE, 18(13), 2241-2251.

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998). Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. ONCOGENE, 17(17), 2235-2249.

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., & Slamon, D. J. (1998). Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. JOURNAL OF CLINICAL ONCOLOGY, 16(8), 2659-2671.

HER-2/neu as a predictive marker of response to breast cancer therapy
Pegram, M. D., Pauletti, G., & Slamon, D. J. (1998). HER-2/neu as a predictive marker of response to breast cancer therapy. BREAST CANCER RESEARCH AND TREATMENT, 52(1-3), 65-77.

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., & Slamon, D. J. (1997). The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. ONCOGENE, 15(5), 537-547.

HER-3 TYROSINE KINASE PATHWAY TARGETS ESTROGEN-RECEPTOR AND PROMOTES HORMONE-INDEPENDENT GROWTH IN HUMAN BREAST-CANCER CELLS
Pietras, R. J., Arboleda, J., Reese, D. M., WONGVIPAT, N., Pegram, M. D., & Slamon, D. J. (1995). HER-3 TYROSINE KINASE PATHWAY TARGETS ESTROGEN-RECEPTOR AND PROMOTES HORMONE-INDEPENDENT GROWTH IN HUMAN BREAST-CANCER CELLS. ONCOGENE, 10(12), 2435-2446.

ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS
Pietras, R. J., Fendly, B. M., CHAZIN, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994). ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS. ONCOGENE, 9(7), 1829-1838.

DIAGNOSIS OF INFECTIVE AND INFLAMMATORY DISORDERS BY FLOW CYTOMETRIC ANALYSIS OF BLOOD NEUTROPHILS
Bentley, S. A., Pegram, M. D., & Ross, D. W. (1987). DIAGNOSIS OF INFECTIVE AND INFLAMMATORY DISORDERS BY FLOW CYTOMETRIC ANALYSIS OF BLOOD NEUTROPHILS. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 88(2), 177-181.